Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Dummer R, Assaf C, Bagot M, et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer. 2007;43:2321–2329.
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776.
   PubMed Web of Science ®Google Scholar
• Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65:8530–8537.
   PubMed Web of Science ®Google Scholar
• Zagouras P, Stifani S, Blaumueller CM, et al. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA. 1995;92:6414–6418.
   PubMed Web of Science ®Google Scholar
• Westhoff B, Colaluca IN, D'Ario G, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA. 2009;106:22293–22298.
   PubMed Web of Science ®Google Scholar
• Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66:6312–6318.
   PubMed Web of Science ®Google Scholar
• Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398–3403.
   PubMed Web of Science ®Google Scholar
• Li J, Cui Y, Gao G, et al. Notch1 is an independent prognostic factor for patients with glioma. J Surg Oncol. 2011;103:813–817.
   PubMed Web of Science ®Google Scholar
• Balint K, Xiao M, Pinnix C, et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest. 2005;115:3166–3176.
   PubMed Web of Science ®Google Scholar
• Lee JY, Song SY, Park JY. Notch pathway activation is associated with pancreatic cancer treatment failure. Pancreatology. 2014;14:48–53.
   PubMed Web of Science ®Google Scholar
• Rahman M, Nakayama K, Rahman M, et al. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol. 2012;138:535–544.
   PubMed Web of Science ®Google Scholar
• Meng RD, Shelton CC, Li YM, et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009;69:573–582.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Iwamoto T, Liu S, et al. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012;18:1109–1119.
   PubMed Web of Science ®Google Scholar
• Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777–1785.
   PubMed Web of Science ®Google Scholar
• Wang J, Wakeman TP, Lathia JD, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010;28:17–28.
   PubMed Web of Science ®Google Scholar
• Mizugaki H, Sakakibara-Konishi J, Ikezawa Y, et al. γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer. Br J Cancer. 2012;106:1953–1959.
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Gjerdrum LM, Biskup E, et al. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2010;116:2504–2512.
   PubMed Web of Science ®Google Scholar
• Gootenberg JE, Ruscetti FW, Mier JW, et al. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med. 1981;154:1403–1418.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Carney DN, Bunn PA, et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood. 1980;55:409–417.
   PubMed Web of Science ®Google Scholar
• Kaltoft K, Bisballe S, Rasmussen HF, et al. A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res. 1987;279:293–298.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42:1014–1030.
   PubMed Web of Science ®Google Scholar
• Lagadec C, Vlashi E, Alhiyari Y, et al. Radiation-induced Notch signaling in breast cancer stem cells. Int J Radiat Oncol Biol Phys. 2013;87:609–618.
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Biskup E, Gniadecki R. Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach? Br J Dermatol. 2010;163:781–788.
   PubMed Web of Science ®Google Scholar
• van der Fits L, Qin Y, Out-Luiting JJ, et al. NOTCH1 signaling as a therapeutic target in Sézary syndrome. J Invest Dermatol. 2012;132:2810–2817.
   PubMed Web of Science ®Google Scholar
• Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist. 2007;12:942–951.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yan X, Duan W, et al. Pterostilbene exerts antitumor activity via the Notch1 signaling pathway in human lung adenocarcinoma cells. PLoS One. 2013;8:62652.
   PubMed Web of Science ®Google Scholar
• Jin SM, Cho HJ, Jung MW, et al. DNA damage-inducing agent-elicited gamma-secretase activity is dependent on Bax/Bcl-2 pathway but not on caspase cascades. Cell Death Differ. 2007;14:189–192.
   PubMed Web of Science ®Google Scholar
• Gallardo F, Sandoval J, Diaz-Lagares A, et al. Notch1 pathway activation results from the epigenetic abrogation of Notch-related microRNAs in mycosis fundoides. J Invest Dermatol. 2015;135:3144–3152.
   PubMed Web of Science ®Google Scholar
• Kopp F, Oak PS, Wagner E, et al. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PloSOne. 2012;7:1–11.
   Web of Science ®Google Scholar
• Brabletz S, Bajdak K, Meidhof S, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. Embo J. 2011;30:770–782.
   PubMed Web of Science ®Google Scholar
• Karpova MB, Gunz D, Okoniewski MJ, et al. Transcriptome adaptation caused by vorinostat/bexarotene combination therapy in advanced cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:8050.
   Web of Science ®Google Scholar
• Weerkamp F, Luis TC, Naber BA, et al. Identification of Notch target genes in uncommitted T-cell progenitors: no direct induction of a T-cell specific gene program. Leukemia. 2006;20:1967–1977.
   PubMed Web of Science ®Google Scholar
• Chadwick N, Zeef L, Portillo V, et al. Identification of novel Notch target genes in T cell leukaemia. Mol Cancer. 2009;8:35. DOI: 10.1186/1476-4598-8-35.
   PubMed Web of Science ®Google Scholar
• Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20:2096–2109.
   PubMed Web of Science ®Google Scholar